Two drugs that slow MRSA's resistance to treatment identified

Share this content:
Researchers at Oregon State University have identified two antibiotics they say are less likely to cause future antibiotic resistance in community-associated strains of methicillin-resistant Staphylococcus aureus.

MRSA is typically found in nursing home and hospital settings, but recent studies have found that the super-bug is making headway in the community at large. So far, the community-based strain is more susceptible to antibiotics, but as with its healthcare-based counterpart, those drugs are likely to lose their effectiveness before long, researchers say. During the study of treatment options for MRSA, the researchers discovered that the antibiotics linezolid and moxifloxacin, when used to treat MRSA, slow the bacteria's ability to resist antibiotics.

The researchers also identified two antibiotics, clindamycin and doxycycline, which accelerate the antibiotic resistance of MRSA. By identifying these types of antibiotics, researchers say they can buy more time to develop new approaches to treating the super-bug. The new research appears in the International Journal of Antimicrobial Agents.